Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab vs Temsirolimus with Chemotherapy in Recurrent Rhabdomyosarcoma
NCT01222715Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2010
- Primary completion
- Jun 2015
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of bevacizumab, temsirolimus in rhabdomyosarcoma (RMS), sponsored by National Cancer Institute. Started Oct 2010; status: completed.
02
Drugs
bevacizumabtemsirolimus
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT01222715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01222715.